Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer

Nano Lett. 2005 Dec;5(12):2426-31. doi: 10.1021/nl051679d.

Abstract

Photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) was evaluated using a supramolecular nanomedical device, that is, a novel dendritic photosensitizer (DP) encapsulated by a polymeric micelle formulation. The characteristic dendritic structure of the DP prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. With its highly selective accumulation on choroidal neovascularization (CNV) lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Carriers / administration & dosage*
  • Drug Carriers / chemistry
  • Glaucoma, Neovascular / drug therapy
  • Glaucoma, Neovascular / metabolism*
  • Glaucoma, Neovascular / pathology
  • Macromolecular Substances / chemistry
  • Male
  • Nanotechnology / methods*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / administration & dosage*
  • Photosensitizing Agents / pharmacokinetics*
  • Porphyrins / administration & dosage*
  • Porphyrins / chemistry
  • Rats

Substances

  • Drug Carriers
  • Macromolecular Substances
  • Photosensitizing Agents
  • Porphyrins